
Global R&D Pipeline
My Favorite
Hot Targets:
CD34
Back
Total number of drugs
13
Phase II and later clinical stages
23.1%
Involving companies
15
Main therapeutic areas
Other Diseases
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stem cell therapeutics (ExCellThera) | Stem cell therapeutics (ExCellThera) | Hematopoietic stem cell therapy | Neoplasms Hemic and Lymphatic Diseases Immune System Diseases Other Diseases | Hematopoietic progenitor cell antigen CD34 agonists Stem cells stimulants | ExCellThera, Inc. | Cordex Biologics, Inc.ExCellThera, Inc. | Approved | European Union Iceland Liechtenstein Norway | 2025-08-25 | United States | Stem cell therapeutics (ExCellThera) | detail > | |||||||||
| Lentiviral Gene Therapy(University of California, San Francisco) | Lentiviral Gene Therapy(University of California, San Francisco) | Gene therapy | Immune System Diseases Congenital Disorders Endocrinology and Metabolic Disease Other Diseases | Hematopoietic progenitor cell antigen CD34 modulators | The University of California, San Francisco | The University of California, San Francisco | Phase 1/2 | Lentiviral Gene Therapy(University of California, San Francisco) | detail > | ||||||||||||
| Retroviral ADA-transduced CD34+ cells(University of California, Los Angeles) | Retroviral ADA-transduced CD34+ cells(University of California, Los Angeles) | Gene therapy | Immune System Diseases Congenital Disorders Endocrinology and Metabolic Disease Hemic and Lymphatic Diseases Other Diseases | Hematopoietic progenitor cell antigen CD34 antagonists | University of California, Los Angeles | University of California, Los Angeles | Phase 1/2 | Retroviral ADA-transduced CD34+ cells(University of California, Los Angeles) | detail > | ||||||||||||
| Autologous CD34+ cells transduced with TNS9.3.55(San Rocco Therapeutics) | Autologous CD34+ cells transduced with TNS9.3.55(San Rocco Therapeutics) | Hematopoietic stem cell therapy | Congenital Disorders Hemic and Lymphatic Diseases Other Diseases | Hematopoietic progenitor cell antigen CD34 modulators | San Rocco Therapeutics | San Rocco Therapeutics | Phase 1 | Autologous CD34+ cells transduced with TNS9.3.55(San Rocco Therapeutics) | detail > | ||||||||||||
| HSC-100 | HSC-100 | Hematopoietic stem cell therapy | Neoplasms Hemic and Lymphatic Diseases | Hematopoietic progenitor cell antigen CD34 modulators Cell replacements | Tatcitus Therapeutics | The Mount Sinai Health System, Inc.Tatcitus Therapeutics | Phase 1 | HSC-100 | detail > | ||||||||||||
| CN118703442 | CN118703442 | Cell therapy | Hemic and Lymphatic Diseases | Discovery | CN118703442 | detail > | |||||||||||||||
| Wiskott-Aldrich Syndrome therapy (ImmunoVec) | Wiskott-Aldrich Syndrome therapy (ImmunoVec) | Gene therapy | Immune System Diseases Congenital Disorders Hemic and Lymphatic Diseases Other Diseases | Hematopoietic progenitor cell antigen CD34 modulators | ImmunoVec, Inc. | ImmunoVec, Inc. | Discovery | United States | Wiskott-Aldrich Syndrome therapy (ImmunoVec) | detail > | |||||||||||
| CD34-mdr1 gene therapy(University of Michigan College of Engineering) | CD34-mdr1 gene therapy(University of Michigan College of Engineering) | Gene therapy | Neoplasms | Hematopoietic progenitor cell antigen CD34 agonists | University of Michigan College of Engineering | Discontinued | CD34-mdr1 gene therapy(University of Michigan College of Engineering) | detail > | |||||||||||||
| OTL-101 | OTL-101 | Hematopoietic stem cell therapy | Immune System Diseases Congenital Disorders Endocrinology and Metabolic Disease Hemic and Lymphatic Diseases Other Diseases | Hematopoietic progenitor cell antigen CD34 modulators Stem cell replacements | Orchard Therapeutics Plc | Phase 2/3 | OTL-101 | detail > | |||||||||||||
| Anti-CD34 CAR-T (Shenzhen Geno-Immune Medical ) | Anti-CD34 CAR-T (Shenzhen Geno-Immune Medical ) | Autologous CAR-T | Neoplasms Immune System Diseases Hemic and Lymphatic Diseases Other Diseases | Hematopoietic progenitor cell antigen CD34 antagonists | Shenzhen Geno-Immune Medical Institute | Phase 1 | Phase 1 | Anti-CD34 CAR-T (Shenzhen Geno-Immune Medical ) | detail > |
Total 13 data
1
2


